Syngene International Ltd

Syngene International Ltd has witnessed a notable 20.26% surge in open interest in its derivatives segment, signalling heightened market activity and shifting investor positioning. Despite a strong intraday price gain of 4.17%, the stock remains under pressure from a broader downtrend, with mixed volume patterns and delivery volumes suggesting cautious sentiment among participants.

Syngene International Ltd, a small-cap player in the healthcare services sector, witnessed a notable 19.5% surge in open interest in its derivatives segment on 13 Mar 2026, signalling heightened market activity and shifting investor positioning. Despite a strong intraday price gain of 4.01%, the stock remains under pressure from a broader negative market backdrop and a recent downgrade in its Mojo Grade to Strong Sell.

Syngene International Ltd, a small-cap player in the Healthcare Services sector, witnessed a notable surge in open interest (OI) in its derivatives segment on 13 Mar 2026, signalling heightened market activity and shifting investor positioning. Despite a strong intraday price gain of 4.31%, the stock remains under pressure from a broader negative sector and Sensex trend, reflecting a complex interplay of bullish bets and cautious sentiment.

Syngene International Ltd (SYNGENE) witnessed a significant 20.6% increase in open interest in its derivatives segment on 13 Mar 2026, signalling heightened market interest and potential directional bets. The stock outperformed its healthcare sector peers and broader indices, reflecting renewed investor optimism despite a prevailing strong sell mojo grade.

Syngene International Ltd, a key player in the Healthcare Services sector, witnessed a notable 20.57% surge in open interest in its derivatives segment on 13 Mar 2026, signalling heightened market activity and shifting investor positioning despite mixed price and volume signals.

Syngene International Ltd has witnessed a notable surge in call option trading ahead of the 30 March 2026 expiry, signalling increased bullish positioning among investors despite a recent downgrade to a Strong Sell rating. The healthcare services company’s stock outperformed its sector and broader market indices, reflecting a complex interplay of market optimism and caution.

Syngene International Ltd has declined to a fresh 52-week low, closing near Rs 381.05, marking a significant downturn in the stock’s performance over the past year. This new low reflects ongoing pressures on the company’s valuation and financial metrics amid broader market weakness.

Syngene International Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 19 January 2026, reflecting a reassessment of the stock’s outlook. However, all fundamentals, returns, and financial metrics discussed below are current as of 06 March 2026, providing investors with the latest perspective on the company’s performance and valuation.

Syngene International Ltd witnessed a sharp gap down at market open today, reflecting heightened market concerns following recent developments. The stock opened at an intraday low of Rs 381.05, marking a 9.78% decline from its previous close and hitting a new 52-week low amid continued downward momentum.

Syngene International Ltd, a key player in the Healthcare Services sector, has touched a new 52-week low of Rs.381.05 today, marking a significant decline amid a sustained downward trend. The stock has underperformed its sector and broader market benchmarks, reflecting ongoing pressures on its financial performance and valuation metrics.

Syngene International Ltd’s shares declined to a fresh 52-week low of Rs.420.8 today, marking a significant downturn for the healthcare services company amid a broader market dip. The stock has now recorded a four-day consecutive fall, shedding 5.8% over this period and underperforming its sector by 0.91% on the day.

Syngene International Ltd’s stock declined to a fresh 52-week low of Rs.426.25 today, marking a significant downturn amid sustained underperformance relative to its sector and benchmark indices. The stock has now recorded a three-day consecutive fall, losing 4.55% over this period, and continues to trade below all key moving averages, reflecting persistent market pressures.

Syngene International Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 19 January 2026. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 23 February 2026, providing investors with the most recent and relevant data to assess the company’s outlook.

Syngene International Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 19 January 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 23 February 2026, providing investors with the latest insights into its performance and outlook.

Syngene International Ltd, a key player in the healthcare services sector, has witnessed a notable surge in open interest (OI) in its derivatives segment, signalling heightened market activity and shifting investor positioning. Despite trading near its 52-week low, the stock has outperformed its sector in recent sessions, prompting a closer examination of volume patterns, market sentiment, and potential directional bets.

Syngene International Ltd, a key player in the healthcare services sector, has witnessed a notable 10.64% surge in open interest in its derivatives segment, signalling heightened market activity and shifting investor positioning. Despite trading close to its 52-week low, the stock has outperformed its sector peers over the past two days, reflecting a complex interplay of bullish and bearish sentiments among traders.

Syngene International Ltd, a key player in the Healthcare Services sector, has reached a new 52-week low of Rs.429, marking a significant decline in its stock price amid ongoing downward momentum and underperformance relative to its sector and broader market indices.